Buy Like Buffett
Watchlist

Flagship explainer

How IOVANCE BIOTHERAPEUTICS, INC. makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$264M · 100%Cost of revenue$173M · 66%Gross profit$90.3M · 34%Operating income−$403M · −153%Income before tax−$393M · −149%Income tax−$2.1M · −1%Net income−$391M · −148%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$264M100%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
Cost of revenue$173M66%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
$90.3M34%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
−$403M−153%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
Income before tax−$393M−149%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
Income tax−$2.1M−1%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
−$391M−148%
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001104659-26-018899 · filed Feb 24, 2026
· event Dec 31, 2025 · retrieved Oct 17, 2026 · annual-row source set
Embed this chart

View the full IOVANCE BIOTHERAPEUTICS, INC. analysis at Buy Like Buffett